Sonya Erickson

Cooley advised Bonum Therapeutics, a biopharmaceutical company focused on creating highly active and less toxic medicines, on its $93 million Series A financing. Partner Sonya Erickson led the Cooley team advising Bonum Therapeutics.

Cooley advised Route, a post-purchase experience platform and package tracking company, on its $200 million Series B financing round, which brings its valuation to $1.25 billion. Lawyers Dave Young, Joseph Kaczorowski, Robert Pollak and Roslyn Akel led the Cooley team advising Route.

Cooley advised Helion Energy, a clean energy company committed to creating a new era of plentiful, zero-carbon electricity from fusion, on its $500 million Series E financing round, which also includes an opportunity for an additional $1.7 billion tied to Helion reaching key performance milestones. Lawyers Sonya Erickson, Colleen Badgley, Ashley Brown, Justine Chiu and Jasjit Grewal led the Cooley team advising Helion.

Cooley advised Within, a Los Angeles-based firm responsible for developing immersive virtual reality fitness app Supernatural, on its agreement to sell to Meta. Partners Anne Lieberman and Dave Young led the Cooley team advising Within.

Cooley advised Eliem Therapeutics on its $92 million initial public offering of 7,360,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Eliem Therapeutics, whose securities now trade on the Nasdaq Global Market under the symbol ELYM, is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Partners Alan Hambelton, Sonya Erickson and Stephen Rosen led the Cooley team.